FTC accuses Endo, other drugmakers of antitrust violations


The Federal Trade Commission is accusing several drugmakers of violating antitrust laws with agreements that delayed availability of cheaper generic versions of two pain treatments. It's the first so-called "pay for delay" case brought by the commission in which a drug's original maker agreed not to sell an "authorized generic" version until well after a generic drugmaker launched its product.



from Biotech News